Anecortave acetate: all 27 studies that test it
Page 1 of 1. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.
- Anecortave Acetate Injection to Treat Steroid-responsive Intraocular Pressure Increase in Cornea Transplant PatientsTerminatedNCT00884039Not applicableResults posted
- A Dose-Volume Study of a Treatment for Elevated IOP Due to Open-Angle Glaucoma or Ocular HypertensionTerminatedNCT00788541Phase 2
- A Multi-Dose Study With a Treatment for Open-Angle GlaucomaWithdrawnNCT00705770Phase 2/3
- Anecortave Acetate Safety in Patients With Open-Angle Glaucoma or Ocular HypertensionCompletedNCT00691717Phase 2/3
- 24 Hour IOP Lowering Efficacy of AL-3789CompletedNCT00643669Phase 2
- Prophylactic Anecortave Acetate in Patients With a Retisert ImplantCompletedNCT00570479Phase 1
- Treatment of Chronic Central Serous Chorioretinopathy With Open-Label Anecortave AcetateCompletedNCT00489840Phase 1/2
- Safety and Efficacy of Anecortave Acetate in Patients With Open-Angle GlaucomaCompletedNCT00451152Phase 2
- A Phase II Study of Anecortave Acetate for the Treatment of Exudative Age-Related Macular DegenerationCompletedNCT00346957Phase 2
- Anecortave Acetate Versus Placebo in AMD Patients Following PDTCompletedNCT00346866Phase 2
- Anecortave Acetate Risk-Reduction Trial (AART)TerminatedNCT00333216Phase 3
- Anecortave Acetate Risk Reduction Trial (AART)TerminatedNCT00332657Phase 3
- Anecortave Acetate in Patients With Open-angle GlaucomaCompletedNCT00320203Phase 2
- Anecortave Acetate for Treatment of Steroid Induced Intraocular Pressure (IOP) ElevationCompletedNCT00315640Phase 2
- Anecortave Acetate Risk-Reduction Trial (AART)TerminatedNCT00307398Phase 3
- Anecortave Acetate in Patients With Exudative Age-related Macular Degeneration (AMD)CompletedNCT00299507Phase 3
- Treatment of Conditions With Open Label-Anecortave Acetate Sterile Suspension ( 15mg.) Where Lesions do Not Meet Acceptable Criteria for Standard Care.CompletedNCT00211484Phase 2
- Treatment of Rubeosis Iridis With Open-Label Anecortave Acetate Sterile Suspension ( 15 mg.).TerminatedNCT00211471Phase 2
- Study of the Combination of Anecortave Acetate and Triamcinolone Acetonide for the Treatment of Exudative Age-Related Macular Degeneration (AMD)CompletedNCT00211419Phase 1
- Treatment of Radiation Retinopathy With Open-Label Anecortave Acetate Sterile Suspension (15 mg)TerminatedNCT00211367Phase 2
- Treatment of Retinal Vein Occlusion (RVO) With Open-Label Anecortave Acetate (15mg.)WithdrawnNCT00211354Phase 2
- Treatment of Idiopathic Perifoveal Telangiectasia (IPT) With Open-Label Anecortave Acetate (15mg.).CompletedNCT00211328Phase 2
- Treatment of Congenital Telangiectasia (Coat's Disease) With Open-label Anecortave Acetate (15mg.)CompletedNCT00211315Phase 2
- Open-Label Posterior Juxtascleral Injections of Anecortave Acetate 15mg Dose for Long Term Use in Patients With AMDTerminatedNCT00065728Phase 3
- An Evaluation of Safety and Efficacy of Anecortave Acetate Versus Placebo in Patients With Subfoveal CNV Due to Exudative AMDCompletedNCT00058994Phase 3
- Anecortave Acetate in Subfoveal Choroidal Neovascularization (CNV) Due to Wet Age-Related Macular Degeneration (AMD)CompletedNCT00051129Phase 3
- Phase 3 Study to Evaluate Anecortave Acetate vs. Visudyne for the Treatment of the Wet Form of AMDCompletedNCT00041483Phase 3